CLSI M43

Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas, 1st Edition

This document provides guidelines for the performance and quality control of agar and broth microdilution antimicrobial susceptibility tests on human mycoplasmas and ureaplasmas.

This document is available in electronic format only.

This edition of the document was corrected in March 2015. Read the full correction notice here, and learn more about our corrections process here.

More Details

Member price:

List Price:

PDF Add to Cart

Details

Chairholder: Ken B. Waites, MD

Date of Publication: October 27, 2011

Order Code PDF: CLSI M43AE
ISBN Number: 1-56238-769-3

Order Code Print: print not available

Edition: First

Pages: 48

CLSI M43 Additional Details

If interested in ordering larger quantities of this document in print, please contact us here.

The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.

This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of September 2016. Because of its value to the laboratory community, it is being retained in CLSI’s library.

CLSI M43 Abstract

Antimicrobial susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism’s identity. Standardized in vitro antimicrobial susceptibility tests are also needed in order to evaluate new antimicrobials against specific groups of organisms in comparison with existing agents. Acquired resistance to one or more classes of antimicrobial agents has now emerged in the major mycoplasmal and ureaplasmal species that infect humans, hence the need to establish accurate and reproducible methods to measure antimicrobial activities in vitro with these organisms.